For the Inventor, By the Inventor

Enter assignee name

Hoofddorp, Netherlands

Abbvie B.v.

USPTO Granted Patents = 13

% Expired Patents = 46.2

CIPO Patents = 1

EPO Patents = 4

Forward Citations = 19

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Wouter I Iwema Bakker (10 out of 21 patents)

Hein K A C Coolen (9 out of 17 patents)

Maria J P Van Dongen (7 out of 8 patents)

4. Adrian Hobson (7 out of 22 patents)

5. Axel Stoit (5 out of 15 patents)

6. Pieter Smid (4 out of 4 patents)

7. Leonardus A J M Sliedregt (4 out of 4 patents)

8. Jacobus A J Den Hartog (4 out of 4 patents)

9. Nicolas J-l D Leflemme (3 out of 4 patents)

10. Raymond Bronger (3 out of 3 patents)

11. Cornelis G Kruse (2 out of 54 patents)

12. Jan H Reinders (2 out of 4 patents)

13. Josephus H M Lange (1 out of 25 patents)

14. Herman H Van Stuivenberg (1 out of 18 patents)

15. Bernard J Van Vliet (1 out of 11 patents)

13 patents: Sort by Forward Citations

1. RE48301 - Fused heterocyclic derivatives as S1P modulators (2020-11-09),

2. 10807991 - Spiro-cyclic amine derivatives as S1P modulators (2020-10-20),

3. 10179791 - Spiro-cyclic amine derivatives as S1P modulators (2019-01-15),

4. 9951084 - Spiro-cyclic amine derivatives as S1P modulators (2018-04-24),

5. 9670220 - Fused heterocyclic derivatives as S1P modulators (2017-06-06),

6. 9662337 - Bisaryl (thio)morpholine derivatives as S1P modulators (2017-05-30),

7. 9227960 - Bisaryl (thio)morpholine derivatives as S1P modulators (2016-01-05),

8. 9096612 - Fused heterocyclic derivatives as S1P modulators (2015-08-04),

9. 9029371 - Bisaryl (thio)morpholine derivatives as S1P modulators (2015-05-12),

10. 8937184 - 1H-imidazole derivatives as cannabinoid CB2 receptor modulators (2015-01-20),

11. 8796262 - Fused heterocyclic derivatives as S1P modulators (2014-08-05),

12. 8735388 - Heterocyclic compounds with affinity to muscarinic receptors (2014-05-27),

13. 8586606 - Heterocyclic compounds with affinity to muscarinic receptors (2013-11-19),

AbbVie B.V. is a global research-driven biopharmaceutical company focused on developing advanced therapies for some of the world’s most complex and critical diseases. With a mission to improve people's lives, AbbVie applies innovative science to provide solutions in multiple therapeutic areas, including immunology, oncology, neuroscience, virology, and general medicine. With a commitment to innovation, patient-centered approaches, and sustainable healthcare solutions, AbbVie aims to make a remarkable impact on global health.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

13 Patents

#11 in Hoofddorp

#507 in Netherlands

#44,950 in the World

Hoofddorp, Netherlands

Abbvie B.v.

Forward Citations = 19

15 inventors:

Wouter I Iwema Bakker (10 out of 21 patents)

Hein K A C Coolen (9 out of 17 patents)

Maria J P Van Dongen (7 out of 8 patents)

4. Adrian Hobson (7 out of 22 patents)

5. Axel Stoit (5 out of 15 patents)

Please report any incorrect information to [email protected]

Loading…